We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: December 7, 2005
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Prostrakan Pharmaceuticals
The purpose of this study is to determine the effectiveness and safety of sublingual fentanyl tablets in relieving breakthrough pain in cancer patients.

Condition Intervention Phase
Pain Cancer Drug: EN3267 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of EN3267 for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients.

Further study details as provided by Prostrakan Pharmaceuticals:

Study Start Date: December 2005
Study Completion Date: January 2009
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   17 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males or females 17 years of age or older
  • Stable cancer-related pain.
  • Are receiving a stable, fixed-schedule oral opioid regimen equivalent to 60 to 1000 mg of oral morphine per day or transdermal fentanyl therapy equivalent to 50 to 300 µg/h, and are on a stable dose of opioid medication for relief of breakthrough pain for at least 14 days prior to screening.
  • Experiencing 1-4 episodes of breakthrough pain per day.
  • Meet the criteria defined in the Eastern Cooperative Oncology Group (ECOG) Performance Status for Grade 0, 1, or 2.

Exclusion Criteria:

  • Are pregnant or lactating.
  • Have uncontrolled or rapidly escalating pain.
  • Have moderate to severe ulcerative mucositis.
  • Have a cardiopulmonary disease that would increase the risk of administering potent opioids.
  • Have neurologic or psychologic disease that would compromise data collection
  • Have any clinically significant condition that would, in the investigator's opinion, preclude study participation.
  • Are currently taking monoamine oxidase inhibitors (MAOIs), or have taken MAOIs within 14 days prior to enrolling in the study.
  • Have received strontium 89 therapy within 60 days prior to entering the study.
  • Have received anti-neoplastic therapy within 2 weeks of study entry that, in the investigator's opinion, will influence assessment of breakthrough pain
  • Have received any investigational drug (non-approved) within 30 days prior to the first dose of study medication, or are scheduled to receive an investigational drug other than EN3267 during the course of the study.
  • Have hypersensitivities, allergies, or contraindications to fentanyl.
  • Have a significant prior history of substance abuse or alcohol abuse.
  • May have difficulty complying with the protocol, as assessed by the investigator.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00262678

United States, North Carolina
Carolinas Pain Institute
Winston-Salem, North Carolina, United States, 27103
Sponsors and Collaborators
Prostrakan Pharmaceuticals
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00262678     History of Changes
Other Study ID Numbers: EN3267-005
First Submitted: December 6, 2005
First Posted: December 7, 2005
Last Update Posted: October 12, 2017
Last Verified: June 2009

Additional relevant MeSH terms:
Breakthrough Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms